BCMA CAR-T

Phase 2Cell therapy

HHebei Senlang Biotechnology Inc., Ltd.

BCMA CAR-T is one of 90 small molecule programs targeting Plasma Cell Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasma Cell LeukemiaRecruiting

Multiple MyelomaRecruiting

Ulcerative ColitisRecruiting

Plasma Cell LeukemiaPhase 2

Recruiting

Multiple MyelomaPhase 2

Recruiting

Ulcerative ColitisPhase 1

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

15 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 8

Elranatamab

Pfizer

Phase 3

27 9

Vepesid

AAvyxa

Phase 3

17 10

Mozobil

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Ulcerative Colitis

NCT07435779

Q3 2028

Phase 2Recruiting

Multiple Myeloma

NCT07106710

Q3 2029

Phase 2Recruiting

Multiple Myeloma

NCT07106736

Phase 2Recruiting

Plasma Cell Leukemia

NCT07106684

Clinical

Trials by Indication[1]

Multiple Myeloma5 trials

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106710·30 enrolled

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626752·50 enrolled

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04447573·20 enrolled

Show 2 more trials

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106736·60 enrolled

Study of BCMA CAR-T in Multiple Myeloma

Unknown status·HHenan Cancer Hospital·Phase 1/2·NCT03322735·10 enrolled

Ulcerative Colitis1 trial

Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study

Recruiting·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT07435779·12 enrolled

Plasma Cell Leukemia1 trial

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106684·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BCMA CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCMA CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCMA CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Senlang Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: HHebei Senlang Biotechnology Inc., Ltd.

BCMA CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q3 2029

Trials by Indication[1]

Multiple Myeloma5 trials

Ulcerative Colitis1 trial

Plasma Cell Leukemia1 trial

References

Drug Info

Quick Facts

Related News